Splenectomy, historically regarded as a curative approach for refractory ITP, is now reserved for chronic or treatment-resistant pediatric cases due to the risk of infection and the availability of thrombopoietin receptor agonists. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.